Three-year Clinical Outcomes of a Sirolimus-eluting Bioresorbable Scaffold (XINSORB) and a Metallic Stent to Treat Coronary Artery Stenosis

Overview

Journal Ann Transl Med

Publisher AME Publishing Company

Date 2020 Dec 14

PMID 33313234

Citations 4

Authors

Yizhe Wu

ZhiFeng Yao

Jiasheng Yin

Jiahui Chen

Juying Qian

Li Shen

Lei Ge

Junbo Ge

Affiliations

Soon will be listed here.

Abstract

Background: Recent studies have shown increased risks of late target lesion failure (TLF) and thrombosis using a bioresorbable scaffold (BRS). However, the results of the ABSORB China study offered a different means of understanding the long-term performance of BRSs. We tested the 3-year clinical outcome of the XINSORB BRS in a multicenter, randomized controlled clinical trial (ChiCTR1800014966).

Methods: Eligible patients with one or two coronary lesions were randomly assigned 1:1 to be treated with XINSORB scaffolds and metallic sirolimus-eluting stents (SESs). The clinical endpoints include TLF [cardiac death, target vessel-related myocardial infarction (TV-MI), or ischemia-driven target lesion revascularization (ID-TLR)], its components, and devised thrombosis.

Results: Three hundred ninety-five patients were enrolled and randomized to the XINSORB (N=200) and SES (N=195) arms. The clinical 3-year follow-up included 95.5% of the XINSORB-treated patients and 92.8% of the SES-treated patients. Dual antiplatelet therapy was at 59.0% of the XINSORB-treated and 52.8% of the SES-treated patients (P=0.34). There were no significant differences in the clinical outcomes between the XINSORB and SES arms, including in TLF (4.0% 6.2%, P=0.29), cardiac death (1.0% 0%, P=NA), TV-MI (1.0% 0%, P=NA), and ID-TLR (3.5% 6.2%, P=0.19). The rate of confirmed/probable device thrombosis in the XINSORB-treated patients was only 1.0% (2/200).

Conclusions: In this XINSORB randomized clinical trial, the XINSORB scaffolds and SESs showed similar efficacy and safety up to the 3-year follow-up. The rates of TLF and device thrombosis were low and comparable between the two arms.

Citing Articles

Bioresorbable coronary scaffolds are ready for a comeback: pros and cons.

Stone G, Biensock S, Neumann F EuroIntervention. 2023; 19(3):199-202.

PMID: 37326377 PMC: 10266378. DOI: 10.4244/EIJ-E-23-00015.

Impact of the Xinsorb Scaffold-Related Parameters on Platelet Reactivity in Patients with Single De Novo Coronary Artery Lesions Undergoing Clopidogrel Treatment.

Yu S, Wang M, Yan M, Wang B, Xu Y Anatol J Cardiol. 2023; 27(7):408-416.

PMID: 37288850 PMC: 10339140. DOI: 10.14744/AnatolJCardiol.2023.3071.

The standard versus prolonged dual antiplatelet therapy after the XINSORB bioresorbable scaffold implantation (SPARTA) trial: study protocol for a randomized controlled trial.

Wu Y, Yin J, Li C, Zhang W, Shen L, Ge L Trials. 2023; 24(1):49.

PMID: 36670441 PMC: 9854195. DOI: 10.1186/s13063-022-07028-8.

Two-stage degradation and novel functional endothelium characteristics of a 3-D printed bioresorbable scaffold.

Yin T, Du R, Wang Y, Huang J, Ge S, Huang Y Bioact Mater. 2021; 10:378-396.

PMID: 34901554 PMC: 8636822. DOI: 10.1016/j.bioactmat.2021.08.020.

References

Natsuaki M, Morimoto T, Furukawa Y, Nakagawa Y, Kadota K, Yamaji K . Late adverse events after implantation of sirolimus-eluting stent and bare-metal stent: long-term (5-7 years) follow-up of the Coronary Revascularization Demonstrating Outcome study-Kyoto registry Cohort-2. Circ Cardiovasc Interv. 2014; 7(2):168-79. DOI: 10.1161/CIRCINTERVENTIONS.113.000987. View

Yamaguchi H, Arikawa R, Takaoka J, Miyamura A, Atsuchi N, Ninomiya T . Association of morphologic characteristics on optical coherence tomography and angiographic progression patterns of late restenosis after drug-eluting stent implantation. Cardiovasc Revasc Med. 2015; 16(1):32-5. DOI: 10.1016/j.carrev.2014.12.005. View

Gilard M, Barragan P, Noryani A, Noor H, Majwal T, Hovasse T . 6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial. J Am Coll Cardiol. 2014; 65(8):777-786. DOI: 10.1016/j.jacc.2014.11.008. View

Song L, Li J, Guan C, Jing Q, Lu S, Yang L . Randomized comparison of novel biodegradable polymer and durable polymer-coated cobalt-chromium sirolimus-eluting stents: Three-Year Outcomes of the I-LOVE-IT 2 Trial. Catheter Cardiovasc Interv. 2018; 91(S1):608-616. DOI: 10.1002/ccd.27465. View

Ali Z, Gao R, Kimura T, Onuma Y, Kereiakes D, Ellis S . Three-Year Outcomes With the Absorb Bioresorbable Scaffold: Individual-Patient-Data Meta-Analysis From the ABSORB Randomized Trials. Circulation. 2017; 137(5):464-479. DOI: 10.1161/CIRCULATIONAHA.117.031843. View

Cutlip D, Windecker S, Mehran R, Boam A, Cohen D, van Es G . Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007; 115(17):2344-51. DOI: 10.1161/CIRCULATIONAHA.106.685313. View

Gao R, Yang Y, Han Y, Huo Y, Chen J, Yu B . Bioresorbable Vascular Scaffolds Versus Metallic Stents in Patients With Coronary Artery Disease: ABSORB China Trial. J Am Coll Cardiol. 2015; 66(21):2298-2309. DOI: 10.1016/j.jacc.2015.09.054. View

Stone G, Ellis S, Gori T, Metzger D, Stein B, Erickson M . Blinded outcomes and angina assessment of coronary bioresorbable scaffolds: 30-day and 1-year results from the ABSORB IV randomised trial. Lancet. 2018; 392(10157):1530-1540. DOI: 10.1016/S0140-6736(18)32283-9. View

Kereiakes D, Ellis S, Metzger C, Caputo R, Rizik D, Teirstein P . 3-Year Clinical Outcomes With Everolimus-Eluting Bioresorbable Coronary Scaffolds: The ABSORB III Trial. J Am Coll Cardiol. 2017; 70(23):2852-2862. DOI: 10.1016/j.jacc.2017.10.010. View

10.

Mauri L, Kereiakes D, Yeh R, Driscoll-Shempp P, Cutlip D, Steg P . Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2014; 371(23):2155-66. PMC: 4481318. DOI: 10.1056/NEJMoa1409312. View

11.

Naganuma T, Fujino Y, Tahara S, Mitomo S, Basavarajaiah S, Nakamura S . Extremely Late Catch-Up Phenomenon After First-Generation Sirolimus-Eluting Stent in the Left Main Stem: Insights From Optical Coherence Tomography. JACC Cardiovasc Interv. 2016; 8(14):e237-9. DOI: 10.1016/j.jcin.2015.06.031. View

12.

Modolo R, Collet C, Onuma Y, Serruys P . SYNTAX II and SYNTAX III trials: what is the take home message for surgeons?. Ann Cardiothorac Surg. 2018; 7(4):470-482. PMC: 6082789. DOI: 10.21037/acs.2018.07.02. View

13.

Stone G, Gao R, Kimura T, Kereiakes D, Ellis S, Onuma Y . 1-year outcomes with the Absorb bioresorbable scaffold in patients with coronary artery disease: a patient-level, pooled meta-analysis. Lancet. 2016; 387(10025):1277-89. DOI: 10.1016/S0140-6736(15)01039-9. View

14.

Serruys P, Chevalier B, Sotomi Y, Cequier A, Carrie D, Piek J . Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial. Lancet. 2016; 388(10059):2479-2491. DOI: 10.1016/S0140-6736(16)32050-5. View

15.

Wu Y, Shen L, Wang Q, Ge L, Xie J, Hu X . Comparison of acute recoil between bioabsorbable poly-L-lactic acid XINSORB stent and metallic stent in porcine model. J Biomed Biotechnol. 2012; 2012:413956. PMC: 3470892. DOI: 10.1155/2012/413956. View

16.

Ge J . Bioresorbable vascular scaffold for the treatment of coronary in-stent restenosis: New dawn or frost on snow?. Catheter Cardiovasc Interv. 2018; 92(4):678-679. DOI: 10.1002/ccd.27880. View

17.

Tijssen R, Kraak R, Hofma S, van der Schaaf R, Arkenbout E, Weevers A . Complete two-year follow-up with formal non-inferiority testing on primary outcomes of the AIDA trial comparing the Absorb bioresorbable scaffold with the XIENCE drug-eluting metallic stent in routine PCI. EuroIntervention. 2018; 14(4):e426-e433. DOI: 10.4244/EIJ-D-18-00335. View

18.

Wu Y, Shen L, Ge L, Wang Q, Qian J, Zhang F . Six-month outcomes of the XINSORB bioresorbable sirolimus-eluting scaffold in treating single de novo lesions in human coronary artery. Catheter Cardiovasc Interv. 2016; 87 Suppl 1:630-7. DOI: 10.1002/ccd.26404. View

19.

Xu B, Yang Y, Han Y, Huo Y, Wang L, Qi X . Comparison of everolimus-eluting bioresorbable vascular scaffolds and metallic stents: three-year clinical outcomes from the ABSORB China randomised trial. EuroIntervention. 2018; 14(5):e554-e561. DOI: 10.4244/EIJ-D-17-00796. View

20.

Yang T, Kim D, Jin H, Cho Y, Chung S, Kim D . "Angiographic late catch-up" phenomenon after sirolimus-eluting stent implantation. Int J Cardiol. 2011; 160(1):48-52. DOI: 10.1016/j.ijcard.2011.03.024. View